Skip to content
Movie Casting Call
Author:
Vaderis Therapeutics AG
Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia
August 11, 2026